Sample Preparation Market - Worldwide Market Shares, Strategies, and Forecasts 2014 to 2020

Sample preparation is one of the crucial steps in analysis of any particular substance or chemical. Analytical procedure usually comprise of steps such as sampling, sample preservation, sample preparation, separation, detection and data analysis. After sampling and sample preservation, the next vital step is usually the sample preparation which consumes over 80% of the analysis time. In almost all cases, sample preparation is an imperative step in analysis because many samples are not ready for direct introduction into analytical instrument. Conventionally, solid-phase extraction (SPE), liquid-liquid extraction (LLE), protein precipitation (PP) and dilute and shoot technique have been used for sample preparation during various analytical procedures. The most recent techniques include solid phase microextraction (SPME), Matrix solid-phase dispersion (MSPD) and membrane assisted solvent extraction (MASE). The ever increasing regulatory requirements for testing substances, chemicals and pharmaceuticals promise a better outlook for the global sample preparation market.

Sample preparation is a prerequisite for analysis to convert a real substance into a sample suitable for analysis. Some of the common sample preparation procedure involves extraction, concentration, cleanup, derivatization, speciation, and transfer to vapor phase. However, the number of steps and/or method used for sample preparation depends on the nature of substance subjected to analysis and the intended data to be analyzed. The products in the global sample preparation products market include automation systems, consumables such as chromatography columns, plates, and accessories including, adaptors, manifolds, reservoirsplastic tubings, and fittings. The customers relying heavily on sample preparation products include those from end-user industries such as pharmaceuticals, biotechnology, and academic research institutes. Since, sample preparation is the most time consuming step in any analysis and end-user industry constantly insists on more efficient products and automation systems to achieve high throughput. The results of analysis directly affect the decision-making process and therefore, this market continues to remain dynamic through regular introduction of more efficient products.

With the recent developments in the pharmaceuticals industry which demand increased sample analysis, the global market for the sample preparation products is expanding at a much faster rate than ever. Among them, sample preparation products for SPE have become indispensible tool in laboratories across the globe. Restricted Access Media (RAM), Molecularly Imprinted Polymers (MIPS) and immunoaffinity sorbents are among important advancements in the sample preparation which enable more selectivity in the sample preparation. The increased selectivity will widen the scope of these techniques particularly in critical areas such as forensic, clinical, pharmaceutical, and biochemical analyses. In similar way, SPE pipette tips, 96 well plates, online-extraction and multifunctional autosamplers offer high throughput analysis. These developments in the sample preparation products market are expected to further propel the global market in the near future.

Downlaod Brochure: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=3855

Geographically, the global sample preparation market can be segmented into four major regions, namely, North America, Europe, Asia-Pacific and Rest of the World. The market for sample preparation in the North America was largest among all regions and will continue to remain at top position during the forecast period from 2014 to 2020. The laboratories in the Asia-Pacific are expected to drive the market in this region

Some of the companies in the global sample preparation market include Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., Danaher Corporation, Illumina, Inc., Merck Millipore, PerkinElmer, Inc. Qiagen, N.V., Roche, Pall Corporation, Waters Corporation, Sigma Aldrich Corporation, and Thermo Fisher Scientific, Inc.

U.S. Vaccines Market to Exhibit 4.30% CAGR 2014-2020 due to Government-led Awareness Initiatives

Transparency Market Research has published a report on the U.S. vaccine market for the 2014-2020 period. According to the report, this market will expand at a CAGR of 4.3% between 2014 and 2020. This report on the U.S. vaccine market presents an insightful and in-depth overview of the current and future growth potential of the human and animal vaccine markets. The title of this report is “U.S. Vaccine Market - Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020” and is available for sale on the company’s website.

A vaccine is a biological preparation that delivers active acquired immunity against a particular disease. It is administered either through needle injections, orally, or by aerosol. Vaccination involves the administration of a killed or weakened organism into the body that develops immunity in the body against that organism. Vaccines cause immunization; there are also some diseases that provide immunization after recovery from the disease.

According to the Centers for Disease Control and Prevention (CDC), vaccination programs across the U.S. have been successful in the eradication of lethal diseases such as polio, smallpox, and diphtheria, while diseases such as tetanus, rubella, and measles have been largely controlled. Vaccination administered as a preventive measure has helped save the lives of millions of individuals in the U.S.

In the U.S., strict regulations imposed by the federal government, which mandate immunization against certain diseases is driving the U.S. vaccines market. Meanwhile, the rising incidence of zoonotic diseases among animals and the high risk of transmitting its associated infection to humans is propelling the growth of the animal vaccines market. Moreover, widespread pet ownership in the country has significantly contributed to the growth of the animal vaccines market in the U.S. Factors such as the rising consumption of poultry and meat products and recent approvals of Prime Pac PRRS+ and Once PMH IN have also bolstered the growth of the U.S. animal vaccine market.

Download Brochure: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=553

On the flip side, the stringent regulatory framework that governs the approval process of vaccines in the U.S. impedes the growth of this market to a certain extent. Moreover, the high cost involved in the research and development of new vaccines will also hamper the growth of this market during the forecast period.

The report segments the U.S. vaccine market into human vaccines and animal vaccine to analyze this market during the forecast period. By vaccine type, the U.S. human vaccine market is divided into adult and pediatric vaccines. By antigen, this market is divided into hepatitis, meningococcal, human papillomavirus (HPV), influenza, pneumococcal, combination vaccines, and others.

The U.S. market for animal vaccines is segmented into companion animal and livestock vaccines. The companion animal vaccines segment is further sub-segmented into canine and feline. In 2013, canine vaccines held a slightly larger share than feline vaccines due to the higher average cost of canine vaccines.

Some of the leading players in the U.S. vaccines market are Novartis International AG, Merck & Co. Inc., Sanofi, GlaxoSmithKline plc, and Merck & Co.

Prescription Hormonal Drugs in Gynecology Market Set to Expand by 2024

Global Prescription Hormonal Drugs Market in Gynecology: Description

Hormonal imbalance in women is caused due to abnormalities in the secretion of estrogen, progesterone and as well as androgens. A wide array of symptoms might be experienced by patients depending on the type of abnormality such as hot flushes, depression, vaginal dryness, excessive hair growth and abnormal vaginal bleeding. Environmental and genetic factors have an influence on women's fertility through their effect on hormonal function. Similarly, dysfunction of the HPO (hypothalamic-pituitary-ovarian) axis and/or other endocrine systems may cause infertility and other gynecological disorders. The correct clinical decision for treating these diseases can be made on pathogenetic basis.

Global Prescription Hormonal Drugs Market in Gynecology: Disease Overview

Disturbances related to the menstrual cycle lead to various syndromes such as polycystic ovary syndrome (PCOS), amenorrhea and premenstrual syndrome (PMS). Of all the above, PCOS is a common hormonal disorder seen among women that in the reproductive age. PCOS is a condition in which appearance of the ovaries in most, but not all women, is enlarged and features a number of tiny cysts located along the outer edge of each ovary. PCOS symptoms are observed in nearly 5% to 10% of women who are in their reproductive age (typically between 12 to 45 years).

PCOS is perceived to be among the leading causes of female sub-fertility. It is also among the most frequently reported endocrine problems in women in the reproductive age. Amenorrhea is a clinical condition wherein menstrual periods do not occur. Besides phases such as childhood, breastfeeding, pregnancy, and menopause, the absence of periods may point toward a problem in the female reproductive system. However, hormonal disruption is also a common cause for the absence of menstrual periods. Similarly, PMS is a medical condition that affects many women with childbearing age and causes variety of physical and psychological symptoms that occur just before menstrual cycle.

The prevalence of hormonal imbalance rate in women is high as the World Health Organization (WHO) estimates that PCOS affected 116 million women worldwide as of 2010 i.e. nearly 3.4% of the global female population. While in case of PMS, according to World Health Organization (WHO), in 2010, 199 million women had premenstrual syndrome i.e. nearly 5.8% of the global female population.

Global Prescription Hormonal Drugs Market in Gynecology: Drivers and Restraints

The major drivers of the hormonal drugs in gynecology market includes high awareness in female population regarding hormonal disorders, continuous research and development activities in the field of women healthcare and various government and organizational programs to educate women about the symptoms, precautions and treatments. The market for hormonal drugs in gynecology can be segmented on the basis of different drugs available in the market, different disease conditions and geography. Various drugs available for the treatment of hormonal disorders includes Depo-Provera, Prometrium, Provera, Alesse, Apri, Desogen, Junel Fe 1/20, Kariva, Loestrin Fe1/20, Vestura and others. Geographic segment of prescription hormonal drugs in gynecology market can be categorized into following regions: North America, Europe, Asia-Pacific and Rest of the World.

Downlaod Brochure: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=12563

Brisdelle (low-dose paroxetine mesylate) product of Noven Pharmaceutical received approval in July 2013 against treatment of menopause condition. Brisdelle is a low-dose formulation of paroxetine mesylate, a selective serotonin reuptake inhibitor. Similarly, the new entity AZD4901 (Oral) is currently under phase II clinical trial for treatment of PCOS and this study is sponsored by Astra Zeneca. It is an interventional type of study including 56 as the target sample size.

The major players of prescription hormonal drugs in gynecology market includes Novartis AG, Pfizer, Inc., Berlex Laboratories, Inc., Ferring Pharmaceuticals, S.A., Duramed Pharmaceuticals, Inc. Xanodyne Pharmaceuticals, Inc., Bayer AG and others.

The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.

Trends in Anxiety Disorders and Depression Treatment: What to Expect in 2016

Transparency Market Research has published a new market study, titled “Anxiety Disorders and Depression Treatment Market - Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020.” The report says that the global anxiety disorders and depression treatment market will display a declining 1.25% CAGR from 2014 to 2020. The market’s valuation will drop from US$22.5 bn in 2013 to US$18.2 bn by 2020.

Depression is a medical condition that affects both physical and mental health. There are several types of depressive disorders that can vary from minor to severe and need specific treatment. Symptoms of depression can cause interference in all areas of an individual’s life, which include work and social relationships. Anxiety disorder is a serious mental disorder that interferes with the ability to lead a normal life. Anxiety disorder is characterized by worry and fear, which is constant and overwhelming, and can lead to serious disability.

The increasing prevalence of depression and anxiety disorders is the major factor driving the global anxiety disorders and depression treatment market, says the report. In addition, the rising geriatric population susceptible to trauma and the decreasing side effects of several drug classes are also driving the sales of depression and anxiety disorder treatment products. However, the market will witness a slowdown due to the patent expiration of major antidepressant drugs, the increasing number of generic drug variants, and a weak pipeline of novel drugs. Furthermore, drug-resistant mental disorders are expected to challenge the growth of this market.

The anxiety disorders and depression treatment market is divided on the basis of drug class and geography. By drug class, this market is segmented into selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), atypical antipsychotics, monoamine oxidase inhibitors (MAOIs), tetracyclic antidepressants (TeCAs), anticonvulsants, beta-blockers, benzodiazepines, and tricyclic antidepressants (TCAs).

In 2013, SNRIs led the market and held a share of more than 30%. However, this segment is expected to display a decelerated growth rate in the coming years.

On the basis of geography, this market is broadly divided into North America, Asia Pacific, Europe, and Rest of the World. Currently, North America is the largest market for anxiety disorders and depression treatment. This is mainly due to a large patient pool of individuals suffering from a range of anxiety disorders and depression. However, the market for anxiety disorders and depression treatment is currently saturated in the U.S. due to the availability of several antidepressant drugs on prescription for the same symptoms. As such, the growth of this market is dependent on the introduction of novel drugs for the same indication.

Get a Sample of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1199

Asia Pacific, on the other hand, will display moderate growth due to the changing lifestyles in emerging economies such as China and India. The increasing mental health disorders in these countries due to work- or personal-life-related stress will drive the anxiety disorders and depression treatment market in this region.

The report mentions key players in the global anxiety disorders and depression treatment market, which are AstraZeneca, GlaxoSmithKline, H. Lundbeck, Johnson & Johnson, Eli Lilly and Company, Forest Laboratories, and Merck & Co.

The global anxiety disorders and depression treatment market is segmented as follows:

Leading Players in Digital Health Market

Global Digital Health Market: Overview

Digital health is technology-enabled care that involves the convergence of digital media, health technology, and mobile devices. It is designed to help patients, care givers, and healthcare professionals access relevant data easily and improve the quality of both social and health care. Digital health is gaining impetus since it provides cost-effective solutions at a time when the demand for healthcare services is persistently increasing.

The rising aging population, increasing price of advanced treatments, and shrinking healthcare expenses by governments have impelled healthcare providers to look for complementing solutions to sustain future social and health care systems. Opportunities for deploying mobile technology in a healthcare set-up have significantly increased in the last few years. The proliferation of smart devices and smartphones has played a crucial role in propagating digital health. Notable developments in bio-sensing wearables such as glucose, blood pressure, and diabetes monitors are further expected to augment the interest in digital health.

Digital health enables access to real-time health care data. Furthermore smartphones and wearable medical devices integrating an increasing range of sensors to facilitate monitoring changes in physiology. Therefore, the applicability of digital health is expected to surge extraordinarily in the near future.

The report presents a granular analysis of the global digital health market, studying the various aspects influencing the market’s trajectory between 2016 and 2023. Factors aiding and inhibiting the growth of the market have been analyzed in detail. The report also presents insights into the strategies adopted by various companies operating in the market.

Global Digital Health Market: Key Opportunities and Threats

Digital health refers to a system or solution that delivers effective health care solutions using IT tools and products. It is possible to provide better and more efficient care compared to traditional healthcare via patient online services and digital diagnostic techniques. Latest digital health technologies such as electronic health records (EHR), wireless technologies, and digital diagnostic systems encompass data such as patient history, medication, allergies, immunization dates, radiology images, diagnosis, laboratory and tests results, treatment plans, and insurance information.

The global digital health market is exhibiting robust growth due to the increasing demand for advanced information systems in the health care industry. Favorable policies by governments and the rising investment by players in the healthcare information system (HIT) have also been aiding the expansion of the digital health market. Additionally, the market is also gaining impetus from the growing demand for remote monitoring services in response to the proliferation of home healthcare services.

On the flip side, certain restraints often associated with the global digital health market include high capital expenditure, privacy and security issues, expenditure incurred on maintenance requirement, and inadequate infrastructure of the healthcare industry in developing countries.

Global Digital Health Market: Regional Outlook

Regionally, North America dominates the global digital health market and is expected to maintain its dominance through the forecast period. This exponential surge witnessed by the regional market is aided by the developed healthcare infrastructure, increased healthcare spending, and the increasing incidence of chronic illnesses in the region.

The digital health market is also witnessing attractive opportunities in Europe. The European market is primarily aided by the increasing geriatric population, rising prevalence of chronic ailments, and technological advancements introduced in the HIT. However, during the forecast period, the Asia Pacific digital health market is expected to report growth at highest rate. The increasing investment in healthcare and IT will support the growth of the digital health market in Asia Pacific.

Download Brochure: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=12473

Global Digital Health Market: Competitive Insight

To present insights into the competition prevailing in the market, the report also profiles companies such as General Electric Company, AT&T Inc., McKesson Corporation, Cisco Systems Inc., and others.

The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.

Global Report on Anti-Obesity Drugs Market

Global Anti-Obesity Drugs Market: Overview

The World Health Organization reveals that global obesity has more than doubled since 1980, with over 1.9 billion adults overweight in 2014, of which, more than 600 million were obese. Percentage-wise, an estimated 39% of adults were overweight and 13% were obese in 2014. An additional 42 million children below the age of five were found to be overweight or obese in 2013. Based on two surveys conducted by the Centers for Disease Control and Prevention, an astounding 68.8% of the U.S. adult population is considered to be overweight or obese. It is no surprise, then, that today, most of the world’s population lives in countries where obesity and overweight are claiming more lives than underweight and malnutrition.

This alarming rise in the prevalence of obesity, particularly in the developed region of North America, has been single-handedly propelling the anti-obesity drugs market. Anti-obesity drugs – both prescription and OTC – are of two main types: Centrally-acting drugs and peripherally-acting drugs. These contain a host of pharmacological agents that control or reduce weight by altering either the absorption of calories or regulating appetite.

This comprehensive research publication offers clients an exhaustive database of accurate, authentic, objective, and the most recent information on the global anti-obesity drugs market. The overall market is segmented based on several key criteria and each segment is thoroughly evaluated to identify the leading and weakest categories. Statistical data and inputs from industry experts support the qualitative data offered in the report and help clients devise actionable and profitable decisions for the future.

Global Anti-Obesity Drugs Market: Key Trends and Regional Outlook

The global market for anti-obesity drugs has been expanding at a significant pace in recent years. With the obvious driving factor being the surge in obesity levels around the globe, this market is also propelled by the strong pipeline of anti-obesity drugs. Advanced medical research by drug-manufacturing companies, medical universities and institutes, and government agencies has also substantially contributed toward the growth of the anti-obesity drugs market.

The anti-obesity drugs market in North America has been flourishing over the years owing to the high level of awareness among the population about obesity and the various risks arising from the medical condition, increased healthcare expenditure, the presence of favorable reimbursement policies, extensive research and development activities in the field, and the increased involvement of government as well as non-government organizations in generating awareness and funding research.

The Asia Pacific market for anti-obesity drugs is anticipated to gain momentum in the coming years thanks to the rise in obese population, resulting from increased spending on processed and packaged foods and the growing consumption of sugar-sweetened beverages. Improving healthcare infrastructure and mounting healthcare expenditure is also expected to drive the market for anti-obesity drugs in APAC.

Global Anti-Obesity Drugs Market: Competitive Landscape Snapshot

The leading companies operating in the global anti-obesity drugs market include Boehringer Ingelheim GmbH, Arena Pharmaceuticals Inc., Takeda Pharmaceuticals Company Limited, Zydus Cadila, Rhythm Pharmaceuticals, Merck & Co. Inc., Eisai Co. Ltd., Novo Nordisk A/S, Orexigen Therapeutics Inc., Zafgen, GlaxoSmithKline PLC, Norgine B.V., Pfizer Inc., and F. Hoffmann-La Roche AG. Owing to the increasing prevalence of obesity in several parts of the world, the degree of competition among players in the anti-obesity drugs market has been on the rise. Companies have been heavily investing in the development of agents with increased weight-loss efficacy and a high safety threshold. This gives players a greater chance of approval from regulatory bodies such as the US FDA.

Get a Sample of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=12461

Companies around the globe are also focused on the development as well as successful commercialization of anti-obesity drugs that are both clinically effective and safe in the long run and also have the potential to generate massive sales and reach blockbuster status. The current portfolio of prescription weight-loss drugs and emerging anti-obesity drugs in pre-clinical or clinical trials acts as a significant force driving the global anti-obesity drugs market.

The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.

Anti-cancer Drugs Market Trends & Forecast up to 2024

Global Anti-cancer Drugs Market: Overview

The World Cancer Research Fund states that in 2012, there were around 14 million new cases of cancer around the world; of these, women accounted for 6.7 million cases and men accounted for 7.4 million cases. This figure is likely to increase to 24 million by 2035. Similarly, according to the World Health Organization, an estimated 8.2 million deaths in 2012 were directly related to cancer and the number of new cancer cases is anticipated to increase by an estimated 70% over the next two decades. Accounting for 13% of the total number of new cases diagnosed in 2012, lung cancer was the most common cancer across the globe, followed by breast cancer (1.7 million new cases), and colorectal cancer (1.4 million new cases).

Cancer mortality can be reduced if the disease is detected and treated early. Timely and correct diagnosis is key to effective and adequate treatment. Today, the global anti-cancer drugs market can be rightly characterized by the enormous amount of innovation that hopes to transform the landscape for patients, providers, and companies alike. SEER (Surveillance, Epidemiology, and End Results) survival statistics reveal that in 1990, only half of all cancer patients lived for five years after diagnosis. This has now increased to two-thirds, a result of gradual but consistent innovation in the anti-cancer drugs market.

This research report serves as a blueprint for all stakeholders in the anti-cancer drugs market as it not only gives them a fresh, objective, and accurate perspective of the global industry but also examines the key factors governing its growth from 2016 to 2024, the report’s forecast period. Leading trends, forces driving the growth, and challenges that lie ahead have been discussed at length, supported by appropriate statistics and inputs from industry experts.

Global Anti-cancer Drugs Market: Key Trends and Opportunities

The rising global incidence of various cancers, including cancer of the breast, prostate, skin, blood, gastrointestinal tract, and lungs, is the primary factor boosting the demand for anti-cancer drugs. In addition to this, the development of advanced therapeutic modalities, such as targeted therapies, chemotherapy, immunotherapy, and hormonal therapies has significantly benefited the anti-cancer drugs market in recent years.

This market is predicted to benefit from the commercialization of follow-on-biologics and patent expiration of several blockbuster drugs. The threat of failure of the drugs, the high cost involved in the development of anti-cancer drugs, and the possible side effects of these drugs are expected to challenge the expansion of the global market in the coming years. However, rising government funds are likely to reduce the negative impact of these obstacles and continue propelling the anti-cancer drugs market.

Global Anti-cancer Drugs Market: Competitive Landscape and Region-wise Outlook

Some of the most prominent players in the global anti-cancer drugs market are Celgene Corporation, Eli Lilly and Company, Roche Diagnostics, Novartis AG, Pfizer, Sanofi, Amgen Inc., GlaxoSmithKline PLC, Merck & Company, and Johnson and Johnson.

Geographically, the international market for anti-cancer drugs is segmented into North America, Europe, Asia Pacific, and Rest of the World. North America presently surpasses all of the aforementioned regional markets and is likely to retain its leading position throughout the duration of the forecast period. Favorable reimbursement policies, the surge in investments by prominent multinational companies in the research as well as development of anti-cancer drugs, and the high adoption rate of immunotherapies are some of the major factors responsible for the growth of the North America anti-cancer drugs market.

Get a Sample for this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=12458

Asia Pacific has been identified as a rather lucrative region for the anti-cancer drugs market owing to the rising awareness regarding the availability of advanced therapies. The increase in healthcare expenditure and per capita disposable income is also likely to contribute toward the future expansion of the Asia Pacific anti-cancer drugs market.

The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.